journal
MENU ▼
Read by QxMD icon Read
search

Clinical Advances in Hematology & Oncology: H&O

journal
https://www.readbyqxmd.com/read/27930619/novel-second-line-treatments-for-hepatocellular-carcinoma-discussion
#1
Catherine T Frenette, Riccardo Lencioni, Richard S Finn
No abstract text is available yet for this article.
December 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930618/developing-a-treatment-plan-for-hepatocellular-carcinoma-the-continuum-of-care
#2
Richard S Finn
No abstract text is available yet for this article.
December 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930617/preserving-the-liver-for-second-line-treatment-of-hepatocellular-carcinoma
#3
Riccardo Lencioni
No abstract text is available yet for this article.
December 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930616/second-line-therapy-for-patients-with-hepatocellular-carcinoma
#4
Catherine T Frenette
No abstract text is available yet for this article.
December 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930645/when-to-initiate-treatment-in-myelofibrosis
#5
Claire Harrison
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930644/immunotherapy-for-the-treatment-of-breast-cancer-checkpoint-blockade-cancer-vaccines-and-future-directions-in-combination-immunotherapy
#6
Heather L McArthur, David B Page
Immunotherapy encompasses both vaccines that direct immune responses to tumor-associated antigens, and checkpoint blocking antibodies that inhibit immune system suppression by targeting key pathways mediated by cytotoxic T-lymphocyte-associated antigen 4, programmed death 1 (PD-1), and programmed death ligand 1 (PD-L1). Both of these approaches currently are being explored as potential strategies for the treatment of breast cancer. Recent studies suggest that immunotherapy is poised to change the therapeutic landscape for some breast cancers...
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930643/hem-onc-news
#7
Devon Schuyler
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930642/adjuvant-treatment-for-renal-cell-carcinoma-do-we-finally-have-a-major-breakthrough
#8
Devin N Patel, Robert A Figlin, Hyung L Kim
Clinical parameters can be used to identify patients at greatest risk for recurrence following nephrectomy for clinically localized renal cell carcinoma (RCC). Molecular tools are being developed to improve risk stratification. An increasing list of available treatments for metastatic RCC continues to provide hope that an effective adjuvant therapy will be identified for patients with high-risk, clinically localized disease. In a phase 3 adjuvant therapy trial (S-TRAC), sunitinib increased median disease-free survival in patients with clear cell RCC who were at very high risk...
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930641/should-treatment-of-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-be-intensive-intensive-treatment-is-not-necessary-at-least-in-induction
#9
Sabina Chiaretti
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930640/should-treatment-of-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-be-intensive-intensive-treatment-is-the-best-treatment-for-these-patients
#10
Nicholas J Short, Elias Jabbour
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930639/new-treatments-for-bladder-cancer
#11
Noah M Hahn
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930638/guideline-recommendations-for-the-prophylaxis-of-invasive-aspergillosis-in-aml
#12
Eunice S Wang
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930637/the-use-of-drug-transporters-as-therapeutic-targets
#13
Kathleen M Giacomini
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930636/what-hematologists-need-to-know-about-acute-hepatic-porphyria
#14
Manisha Balwani
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930635/optimal-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer
#15
Jeffrey D Bradley
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930634/letter-from-the-editor-ode-to-bob
#16
Bruce D Cheson
No abstract text is available yet for this article.
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930620/atypical-hemolytic-uremic-syndrome-ahus-essential-aspects-of-an-accurate-diagnosis
#17
Jeffrey Laurence, Hermann Haller, Pier Mannuccio Mannucci, Masaomi Nangaku, Manuel Praga, Santiago Rodriguez de Cordoba
Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a rare, life-threatening, systemic disease. When unrecognized or inappropriately treated, aHUS has a high degree of morbidity and mortality. aHUS results from chronic, uncontrolled activity of the alternative complement pathway, which activates platelets and damages the endothelium. Two-thirds of aHUS cases are associated with an identifiable complement-activating condition. aHUS is clinically very similar to the other major TMAs: Shiga toxin-producing Escherichia coli (STEC)-HUS, thrombotic thrombocytopenic purpura (TTP), and disseminated intravascular coagulation (DIC)...
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930633/hem-onc-news
#18
Devon Schuyler
No abstract text is available yet for this article.
October 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930632/highlights-in-polycythemia-vera-from-the-2016-eha-congress
#19
Srdan Verstovsek
Meeting highlights from the European Hematology Association congress, June 9-12, Copenhagen, Denmark.
October 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27930631/cd19-targeted-car-t-cells-as-novel-cancer-immunotherapy-for-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia
#20
Marco L Davila, Renier J Brentjens
Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors. One type of immunotherapy involves the adoptive transfer of T cells that have been genetically modified with a chimeric antigen receptor (CAR) to target a tumor. These hybrid proteins are composed of the antigen-binding domains of an antibody fused to T-cell receptor signaling machinery. CAR T cells that target CD19 recently have made the jump from the laboratory to the clinic, and the results have been remarkable...
October 2016: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"